Anteris Technologies Ltd. overnight presented 30-Day clinical data for its full cohort of 13 patients implanted with DurAVR THV during its First-In-Human (FIH) trial. The annual Transcatheter Cardiovascular Therapeutics (TCT) medical conference, held in Boston, MA, September 16-19, 2022, attracting more than 10,000 attendees from around the world. Key 30-Day Results: 100% procedural success with no incidence of death, stroke, bleeding, reoperation, reintervention, myocardial infarction, or device deficiency (n=13).

30-day echo demonstrated excellent haemodynamics: mean pressure gradient 9.02 mmHg, effective orifice area 2.00 cm2, and extensive mean valve leaflet coaptation length of 8.3 mm. 2D MRI showed DurAVR being the first aortic valve replacement (TAVR or SAVR) to demonstrate restoration of normal laminar flow dynamics.